#Famotidine Leads to Improved #COVID19 Patient Outcomes based on Retrospective Case Series Led by Cold Spring Harbor Laboratory: A group of prominent New York-based physicians and scientists led by Cold Spring Harbor Laboratory, Northwell Health Cancer institute conducted a retrospective case series targeting ten (10) non-hospitalized patients with SARS-CoV-2, the virus behind the COVID-19 pandemic. It has been alleged that the over-the-counter histamine-2 receptor antagonist called Famotidine could possibly address the novel coronavirus. This insight originally derived from the analysis of Dr. Robert Malone and team associated with the U.S. government research contracts as well as observations of a prominent physician and research named Dr. Michael Callahan after his analysis of over 6,000 patient records at the Wuhan pandemic epicenter. After monitoring and quantitatively analyzing the longitudinal changes in patient reported outcome measures of patients who had been self-administering high-doses of Famotidine orally, the Cold Spring Harbor Laboratory and Northwell Health investigational team found that not only are high doses well tolerated but they are associated with improved patient-reported outcomes in non-hospitalized patients with COVID-19. Meanwhile, a large study at Northwell has commenced in April, including both hydroxychloroquine and Famotidine but there is uncertainty with the use of the anti-malarial drug moving forward. Story Reference Link: https://www.trialsitenews.com/famotidine-leads-to-improved-covid-19-patient-outcomes-based-on-retrospective-case-series-led-by-cold-spring-harbor-laboratory/ +++ please note there is a mispronunciation of Famotidine and we are aware. Thank you #INOVIOPharmaceuticals & Korean Government Close Deal: INO-4800 Phase I/II Trial to Commence in Korea Late June: INOVIO (NASDAQ: INO), the International Vaccine Institute (IVI), and Seoul National University Hospital announced a partnership to commence a Phase I/II clinical trial of INO-4800, INOVIO’s COVID-19 vaccine candidate. A formal signing ceremony occurred involving of key principals for this important event in Korea. The clinical trials will start later in June. Story Reference Link: https://www.trialsitenews.com/inovio-pharmaceuticals-korean-government-close-deal-ino-4800-phase-i-ii-trial-to-commence-in-korea-late-june/ ... https://www.youtube.com/watch?v=Mvqf9FgV_YI

In Slovakia, a team of researchers with expertise in clinical pharmacology analyzed data associated with spontaneous reports of suspected adverse reactions post-administration with COVID-19 vaccines. Represented by Stefan Lassan, corresponding author affiliated with Slovak Medical University, and Bratislava University Hospital, both in Slovakia, and colleagues had their findings published earlier in the year in the peer review journal Frontiers Pharmacology. This study looks into COVID-19 vaccination rates in the Slovak Republic, where the vaccination rate was at 58%, well below the target below the World Health Organization's targeted 70%. One of the key reasons for hesitancy in this Eastern European nation: concern about serious adverse events. Thus, the importance of this study is to review the incidence of reported adverse reactions of authorized COVID-19 vaccines which in Slovakia include Comirnaty (Pfizer); Vaxzervia (AstraZeneca), and Spikevax (Moderna) registered with the State Institute for Drug Control between January 1, 2021, and May 31, 2021. Conducting this retrospective analysis, the researchers report on this first analysis targeting the nation of Slovakia involving the incidence of reported adverse reactions associated with COVID-19 vaccines. While tracking spontaneous adverse events has been difficult, given the call for reporting on such events during the study time period, the study authors report a significant increase in such reports—a five-fold increase in vaccine-related incidents in just the first half of 2021. The AstraZeneca jab was associated with the highest rate of suspicious serious adverse reactions. ------------------------------------ Join The Conversation! | https://trialsitenews.com/ ... https://www.youtube.com/watch?v=dmxN-Cph8ao